Vertex Pharmaceuticals recently announced plans to acquire Crinetics Pharmaceuticals for $10 billion in cash, marking what could be the largest deal in its history. This acquisition is still pending finalization but would significantly expand Vertex’s capabilities in endocrinology by adding Crinetics’ promising drug candidates to its portfolio. The move highlights the ongoing trend of big pharmaceutical firms snapping up smaller biotechs to fast-track their development and market entry. As the deal progresses, analysts speculate it may be just one of many major transactions in a rapidly evolving sector.
With the biopharmaceutical industry witnessing a surge in mergers and acquisitions, Viking Therapeutics has begun attracting attention as a potential target. The company is building a strong presence in the booming weight-loss market through its innovative pipeline. Its lead product, VK2735, is in phase 3 clinical trials and has already shown promising results. Additionally, Viking plans to start late-stage trials for an oral version of the drug by the end of the year. These developments could position Viking as a key player in the obesity treatment space, especially as demand for effective therapies continues to grow.
The U.S. Centers for Disease Control and Prevention reports that more than 70% of American adults are classified as overweight or obese. Excess weight is a major risk factor for numerous health complications, including diabetes, heart disease, and metabolic syndrome. With obesity rates rising, the need for effective treatments has never been higher. Recent advancements in anti-obesity medicines have provided patients with new options to manage their weight and reduce their risk of developing serious health conditions. This growing demand has fueled a surge in interest among pharmaceutical companies eager to enter the expanding market.
Viking Therapeutics is focusing much of its research on VK2735, a dual GLP-1 and GIP agonist. This compound works by mimicking gut hormones that help regulate satiety and insulin release, similar to Eli Lilly’s Zepbound, which has become the leading weight-loss therapy in the market. By targeting these two pathways simultaneously, Viking aims to create a more effective and durable treatment option. If successful, the drug could compete directly with existing weight-loss medications while offering potential improvements in efficacy and convenience.
Early clinical data for VK2735 show impressive results. In phase 2 trials, the drug achieved an average weight loss of 13.1% in just 13 weeks. This compares to Zepbound’s reported average of 20.2% over a much longer 72-week trial period. While it is true that weight loss is typically most pronounced in the initial stages of treatment, Viking’s early numbers suggest strong potential. However, the real test will come when the drug advances to late-stage studies and faces a more rigorous evaluation of its long-term effectiveness and safety profile.
In addition to VK2735, Viking is developing VK3019, another weight-loss candidate that recently entered phase 1 trials. If the drug demonstrates strong efficacy and a favorable safety profile, it could further strengthen Viking’s pipeline and enhance its appeal to potential acquirers. Analysts are closely watching the company, with many forecasting a potential 181% increase in its stock price if the drug trials go well. However, such projections come with a significant caveat: the company is on the brink of a major binary event—its phase 3 data readout—which could either propel the stock to new heights or lead to a steep decline if results fall short.
Why Pharma Companies Are Buying Now
Developing new drugs from scratch is both expensive and time-consuming, often requiring years of research and hundreds of millions in investment. Given these challenges, many pharmaceutical companies are opting to acquire biotechs with already developed or late-stage assets. This strategy allows them to bypass the early stages of development and move quickly toward market entry. The obesity market, in particular, is a prime target for such acquisitions due to its rapid growth. Market forecasts estimate it will reach $190 billion in value by 2035, up from $79 billion in the previous year. The potential for high returns is driving companies to look for promising mid-cap biotechs like Viking Therapeutics.
Viking’s phase 3 trials for VK2735 are expected to conclude by late 2027. Strong results could significantly boost the company’s valuation and attract interest from large pharmaceutical players. However, if the data do not meet expectations, the stock could suffer a sharp decline, making it difficult for the company to recover. This high-risk, high-reward profile makes Viking an attractive but volatile investment. Investors considering the stock should carefully weigh the potential for major gains against the risks associated with clinical trial outcomes and regulatory hurdles. With the anti-obesity market expanding rapidly, Viking’s pipeline could make it a key player—if it can successfully navigate the next stage of its development.